Skip to main content
TIBET AIM PHARM. INC. logo

TIBET AIM PHARM. INC. — Investor Relations & Filings

Ticker · 002826 ISIN · CNE100002C39 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,085 across all filing types
Latest filing 2019-04-23 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 002826

About TIBET AIM PHARM. INC.

https://www.emyy.cn

Tibet Aim Pharm. Inc. is a pharmaceutical enterprise focused on the research, development, production, and distribution of medicinal products. The company integrates traditional Tibetan medicine with modern pharmaceutical manufacturing processes to develop a diverse portfolio of treatments. Its core product range typically includes cardiovascular medications, digestive system therapies, and specialized herbal formulations derived from high-altitude botanical sources. Tibet Aim Pharm. Inc. emphasizes the modernization of traditional formulas through rigorous clinical testing and standardized production techniques. The company serves healthcare providers and patients by providing therapeutic solutions that bridge ancient medical knowledge with contemporary scientific standards.

Recent filings

Filing Released Lang Actions
关于召开2018年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2018 Annual General Meeting (AGM) of the company 西藏易明西雅医药科技股份有限公司. It includes information about the meeting date, location, voting methods (both in-person and online), agenda items to be discussed and voted on, registration procedures, contact details, and proxy forms. The document does not contain financial statements or detailed financial performance data but rather focuses on the logistics and agenda of the AGM. This matches the definition of 'AGM Information' which includes presentations and materials shared during the Annual General Meeting. The document length is about 4920 characters, which is consistent with a detailed meeting notice rather than a full annual report or other financial filings. Therefore, the appropriate classification is AGM Information (AGM-R).
2019-04-23 Chinese
2018年年度报告摘要
Annual Report Classification · 95% confidence The document is titled "西藏易明西雅医药科技股份有限公司 2018 年年度报告摘要" which translates to "Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. 2018 Annual Report Summary." It contains detailed financial data for the year 2018, including revenue, net profit, earnings per share, and asset totals. It also discusses business operations, accounting policy changes, shareholder information, and management commentary on the year's performance. The document is comprehensive and covers the full fiscal year 2018, consistent with an annual report. It is not a brief announcement or a presentation, nor is it a transcript or a regulatory filing. The length (13,670 characters) and content confirm it is the actual annual report summary, not just an announcement of the report. Therefore, the appropriate classification is Annual Report (10-K). FY 2018
2019-04-23 Chinese
华西证券股份有限公司关于公司使用闲置募集资金及自有资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from Huaxi Securities regarding the use of idle raised funds and own funds by Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. for cash management. It references the approval by the China Securities Regulatory Commission and details about the initial public offering and the use of funds for investment in safe, liquid, and principal-guaranteed financial products. The document includes internal approvals by the board and supervisory board and the sponsor's agreement. It is a formal verification or audit opinion related to the use of funds, not a full financial report or earnings release. The document length is short (1560 characters), and it is a standalone audit or verification report rather than an announcement or a full annual/interim report. Therefore, it fits best under Audit Report / Information (AR). FY 2016
2019-04-23 Chinese
华西证券股份有限公司关于公司2018年内部控制自我评价报告和内部控制规则落实自查表核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an internal control self-evaluation report and internal control rules implementation checklist for the year 2018, issued by Huaxi Securities as the sponsor institution for Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. It includes detailed descriptions of internal control environment, implementation, fundraising management, and compliance with regulatory requirements. The document is a verification opinion (核查意见) on the internal control self-evaluation report and related checklists, indicating it is an audit or review of internal controls rather than a full annual report or financial statement. The document length is 3887 characters, which is relatively short and focused on internal control evaluation and compliance. It does not contain full financial statements or comprehensive annual report content. It is not a certification letter or a brief announcement but a detailed audit opinion on internal controls. Therefore, the document fits best into the category of Audit Report / Information (AR), which covers standalone audit reports and internal control evaluations, excluding full annual reports. FY 2018
2019-04-23 Chinese
关于和子公司续签《借款协议》的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company regarding the renewal of a loan agreement with its subsidiary, involving the use of funds raised from a previous public stock issuance. It details the background of the fundraising, the use of the funds, the loan amount, terms, and the purpose of the loan. It includes opinions from independent directors, the supervisory board, and the sponsoring institution, confirming compliance with regulations and the appropriateness of the loan. The document is a formal disclosure of a financing activity related to capital raised and its deployment within the company group. It does not contain financial statements or detailed financial performance data, nor is it a report or transcript. It is an update on capital/financing activities, specifically the use of raised funds to provide a loan to a subsidiary. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 4062 characters, which is consistent with an announcement rather than a full report.
2019-04-23 Chinese
2018年度内部控制自我评价报告西
Audit Report / Information Classification · 95% confidence The document is titled '2018 年度内部控制自我评价报告' which translates to '2018 Annual Internal Control Self-Evaluation Report'. It is a detailed report on the company's internal control evaluation for the year ending December 31, 2018. The content includes descriptions of internal control environment, risk assessment, control activities, information and communication, and internal supervision. It also discusses the standards for identifying internal control deficiencies and the results of such evaluations. The document is comprehensive, over 10,000 characters, and contains substantive information about internal controls rather than just an announcement or certification. This type of report is typically classified as an Audit Report / Information (AR) because it focuses on internal control evaluation, which is part of audit-related disclosures but is not a full annual report or financial statement. It is not an Annual Report (10-K) because it does not cover full financial performance or company activity broadly, nor is it a Regulatory Filing (RNS) or Report Publication Announcement (RPA) since it contains the full report text. Therefore, the best fit is Audit Report / Information (AR). FY 2018
2019-04-23 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.